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the Annual Scientific Meeting of the Heart Failure Society
f America (HFSA) brings together health care profession-
ls who are dedicated to improving the diagnosis, treatment,
nd quality of life for individuals affected by heart failure
HF). During the 2.5-day meeting, attendees had an op-
ortunity to hear about the latest developments in research
both basic and clinical), learn about the latest technologies
sed to treat HF, attend small “how to” sessions on focused
opics, and hear about the latest clinical trials and guide-
ines. The attendance at this year’s 7th annual meeting
roke a new record with 3,400 registrants, compared with
,500 registrants for last year. This is a testament of the
uccess of the meeting in addressing the needs of this
edicated community. The meeting had over 30 sessions
nd obviously not all can be highlighted. This paper
rovides an overview of four clinical sessions, as well as the
asic science portions of the scientific program.
PENING PLENARY SYMPOSIUM—HEART
AILURE 2003: FROM CELLS TO POPULATION
tem and progenitor cells for repair. Dr. Michael Schnei-
er (Baylor College of Medicine, Houston, Texas) opened
he plenary symposium on the topic of stem and progenitor
ells for cardiac repair. Intrinsic cardiac restorative growth is
oo meager to match the demands after acute cell death in
yocardial infarction (MI) or chronic sporadic cell death in
F. Currently, a variety of cell types show promise for
yocardial regeneration, although the biologic understand-
ng of this process is still primitive. Skeletal muscle cells have
een used in clinical trials. They improve ventricular func-
ion, but without transdifferentiating into cardiomyocytes or
onnecting with cardiomyocytes, and are a source of ar-
hythmias. Bone marrow-derived cells—hematopoietic and
esenchymal stem cells and circulating endothelial progen-
tor cells or hemangioblasts—are also promising as sources
f autologous cells. The phase I trials to date are encour-
ging, but it is unclear whether benefits are related to
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ngland Medical Center and Tufts University School of Medicine, Boston, Massa-
husetts.
Manuscript received January 6, 2004; accepted January 14, 2004.yocyte formation or, alternatively, to angiogenesis or an
ltered remodeling process. Human embryonic stem cells have
he best proven ability to form all cell types and hold
remendous promise for therapy, but studies on these cells
ave been limited by religious or ethical objections.
Therefore, the most intriguing question is whether the
eart actually has its own reservoir of repair cells that might
e exploited to replace damaged myocardium more effec-
ively. The answer appears to be “yes,” and the possible
andidates to date are the side-population (SP) cells, c-kit
ells, and Sca-1 cells. Dr. Schneider’s laboratory has
ocused on the latter, identified using the Sca-1 marker
stem cell antigen-1). These are small interstitial cells that
xpress many cardiac transcription factors, but not cardiac
tructural genes, and are viewed as predisposed to convert
nto cardiac muscle itself. This can be triggered in cell
ulture by using a drug (azacytidine), partly dependent on a
eceptor for growth factors with known importance for
ardiac development in the embryo, called “bone morpho-
enic proteins.” Given systemically, cardiac Sca-1 cells
ome specifically to the infarct border zone and differentiate
fficiently in vivo.
The future challenge for stem cell research will be to focus
n stem cell mobilization and stem cell engineering, in an
ttempt to identify control systems for proliferation, differ-
ntiation, myocyte connectivity, and ultimately organ func-
ion and host survival.
ellular apoptosis and survival in HF. Dr. Richard Kitsis
Albert Einstein College of Medicine, Bronx, New York)
hen presented a discussion on cell survival and apoptosis.
he ability to prevent apoptosis or programmed cell death,
articularly in ischemia-reperfusion, will have important
alutary effects on HF development. During a typical
nfarction, 5% to 30% of myocytes in the infarct zone and
.1% to 0.3% in the remote zone undergo apoptosis. This is
n contrast to the baseline apoptosis rate of 0.01% to 0.001%
n the normal myocardium. Apoptotic pathways in myo-
ytes can be triggered by death receptor signals coupled to
rocaspase-8. Additional triggers can arise from an extra-
ellular stimulus that activates Bax and releases
ytochrome-c from mitochondria. This, in turn, activates
paf-1 and procaspase-9 and, together with caspase-8,
eads to caspase-3 activation and execution of cell death. In
he setting of ischemia-reperfusion, inhibition of apoptosis,
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Highlights of 2003 Heart Failure Society of America March 17, 2004:1103–9sing genetic manipulations, reduces the infarct size by 50%
o 60% and improves cardiac function. Similar results are
btained with the newer caspase inhibitors, where sustained
eductions in infarct size and improvements in cardiac
unction are observed, even when administration of the drug
s delayed 1 h from the onset of ischemia.
Does apoptosis directly contribute to HF? Conditional
ctivation of a caspase gene in the mouse myocardium leads
o cardiomyopathy. Conversely, inhibition of apoptosis with
aspase inhibitors improves cardiac dysfunction and reduces
ortality in several models of HF. Thus, at least in rodent
odels, there is a causal link between apoptosis and HF.
So could anti-apoptosis therapies be used to treat acute
I (ischemia-reperfusion) and chronic HF? Given long-
erm safety concerns associated with chronic apoptosis
nhibition, the first realistic clinical target for apoptosis
nhibition is likely to be acute ischemia-reperfusion. Later,
t may be possible to assess the risk/benefit ratio of apoptosis
nhibition for chronic HF. In either case, it may be possible
o combine anti-apoptosis inhibition with the cell-based
herapy discussed earlier.
linical cell therapy in the HF patient. Dr. Richard
eisel (University of Toronto Faculty of Medicine, To-
onto, Canada) provided an overview of clinical develop-
ents in clinical applications of regenerative medicine to
ate. The pioneering efforts of skeletal myoblast transplanta-
ion has led to ventricular arrhythmias in 4 of 12 patients,
equiring placement of an implantable cardioverter-
efibrillator, but the cells improved regional wall motion,
ven though they did not beat with the surrounding
yocytes. The major clinical issues to resolve are the modes
f delivery of cells: intracoronary, endocardial, or the novel
pproach of using coronary venous access to deliver cells
nto the mid-myocardium of the infarct region.
Currently, the most promising sources of stem cells or
rogenitor cells are from the bone marrow or the heart.
uccessful implantation improved myocardial perfusion to
he ischemic region and prevented dilation of the ventricle.
he other challenges are the optimal cell types, the timing
f engraftment, and how to improve the survival of the
raft. The combination of the cells with gene transfer of
urvival factors may be a promising approach.
Future approaches to the cellular remodeling may include
urgical resection, such as that being tested in the Surgical
reatment for Intra-Cerebral Hemorrhage STICH trial,
ogether with a cellular patch graft into the infarct zone.
he salutary mechanisms of these cellular grafts likely reside
n their ability to increase matrix metalloproteinases and
ecrease their inhibitors (tissue inhibitors of metalloprotein-
se [TIMP]). This leads to stabilization of matrix, cell
reservation, prevention of apoptosis, improvement of an-
iogenesis, and ultimately improvement in cell survival.
ap for the future care of patients with HF. Dr. Harlan
rumholz (Yale University, New Haven, Connecticut) ex-
ressed concern about the state of the health care system for
ur HF patients, as it is currently unsafe, ineffective, (nequitable, inefficient, and non–patient-centered. We need
o rapidly evolve to a safe and patient-centered health care
ystem to deliver better care to our patients.
To do so, we first need to expand our knowledge base. We
eed new insights from efficacy trials to effectively prevent
F; we need new information on means of delivering
ffective clinical care to prevent HF. We need to have
nowledge of what treatments actually improve outcomes,
s well as what systems to implement to maximize benefit
nd efficiency.
We also need knowledge derived from outcomes research,
enerating evidence that can support clinical decision-
aking, improve clinical practice, and guide health policy.
ow are we doing now, and how can we do it better?
urrently, there is no national surveillance database for HF.
e need to have ongoing monitoring of HF outcomes,
long with associated costs, manpower, and other resources
equired. For example, disease management can achieve a
6% reduction in the relative risk of combined mortality and
orbidity for the HF patient. However, it is not seen as a
riority within the medical community. Indeed, HF care
nterdisciplinary teams are at the leading edge of this
oncept of care, but the health care system must appreciate
he value of this paradigm and accommodate this change in
oncept.
To move health care to the next level, we also need to
ractice preference sensitive care, whereby a patient’s personal
hoices, such as tradeoffs in quality versus quantity of life,
ust be individually decided. We also need to practice
esource sensitive care, whereby the balance of societal,
ommunity, and individual patient needs is carefully
eighed, and efforts toward increased standardization of
ccess and expenditure should be made.
We need to realize the need to change and take actions to
hange the culture of our health care system. We must
ecognize the need for change, seek ways to improve our
utcomes, and move from a paradigm of individual maverick
hysician to integrated teams. We can enhance system per-
ormance through a concerted effort, and this is not a sign of
eakness or a threat to the science and art of medicine. We
eed to start now.
ASIC SCIENCE SYMPOSIUM
he inaugural Basic Science Symposium on Sunday focused
rimarily on the role of regulators of gene transcription in
ormal and pathologic growth of the heart. Presentations by
r. Eric Olson (Keynote Address; University of Texas,
outhwestern Medical Center, Dallas, Texas) and Dr.
onathan Epstein (University of Pennsylvania School of
edicine, Philadelphia, Pennsylvania) helped clarify seem-
ngly contradictory reports on the role of histone de-
cetylases (HDACs) in regulating cardiac hypertrophy. The
DACs are enzymes that remove acetyl groups from
istones, proteins associated with deoxyribonucleic acid
DNA). De-acetylation of histones blocks gene transcrip-
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March 17, 2004:1103–9 Highlights of 2003 Heart Failure Society of Americaion, and thus HDACs are negative regulators of transcrip-
ion. In the heart, HDACs were initially identified as
nhibitors of hypertrophy, as deletion of HDAC-5 and -9 in
he mouse led to spontaneous hypertrophy. Similarly, Joan
eller Brown’s work with a transgenic mouse expressing
aMKIIB, a protein kinase that, when activated by hyper-
rophic stimuli, leads to the export of class II HDACs from
he nucleus, thus inactivating them, also suggests a critical
ole for HDACs in blocking hypertrophy, as her mouse also
ad spontaneous hypertrophy. However, pharmacologic
nhibitors of HDACs, which might have been predicted to
imic the phenotype of the knockouts and to increase
ypertrophy, have recently been reported to block hypertro-
hic growth in cardiomyocytes in culture. The Olson and
pstein laboratories have found that these seemingly con-
radictory results may relate to the fact that HDAC-5 and
9, which are class II HDACs, repress transcription of
rohypertrophic gene programs, whereas class I HDACs
ay repress transcription of antihypertrophic genes. This
electivity may be mediated, at least in part, by a protein
alled Hop (homeodomain only protein), which recruits
lass I HDACs specifically to antihypertrophic genes regu-
ated by the transcription factor called serum response
actor. In agreement with this, a transgenic mouse express-
ng Hop in the heart has severe hypertrophy and fibrosis and
ies suddenly. Importantly, trichostatin A, an HDAC
nhibitor, blocked isoproterenol-induced hypertrophy. Be-
ause HDAC inhibitors are currently in clinical trials for
ancer and appear to be well tolerated, this sets up the
ossibility of employing HDAC inhibitors as potentially
ery important antihypertrophic therapies. However, class-
r isoform-specific inhibitors may be required.
The study of cardiac development has largely focused on
enetic determinants. In a departure from the main theme
f the session, Dr. Scott Fraser (California Institute of
echnology, Pasadena, California) reviewed emerging evi-
ence that intracardiac fluid forces function as an epigenetic
actor to critically regulate embryonic development of the
eart. Fraser and his co-workers have used remarkable in
ivo imaging technologies to demonstrate high levels of
hear forces and vortical flow in the developing zebrafish
eart, which is approximately the size of a coarse human
air. They found that the levels of shear forces were well
bove the threshold for induction of gene expression in
tudies of endothelial cells in culture. By physically inter-
ering with inflow or outflow of the heart at 37 h after
ertilization, they were able to test the hypothesis that these
hear forces might modulate embryonic development of the
eart. They found that the reduction in shear stress led to a
ailure of one of the chambers of the heart to develop, a
ailure of the heart to loop (a necessary step in cardiac
evelopment), collapse and fusion of the walls of the inflow
nd outflow tracts, and abnormal valve development. These
tudies demonstrate that direct interference with intracar-
iac fluid forces has profound effects on valve formation,
hamber differentiation, and organ morphology. Becausepproximately 40% of congenital heart defects involve a
alvular abnormality, these studies raise the possibility that
hese valvular abnormalities worsen the phenotype of the
irth defect via altering intracardiac fluid forces.
Dr. Michael Schneider (Baylor College of Medicine,
ouston, Texas) in the Sunday Morning Symposium, and
is fellow, Dr. Motoaki Sano (finalist in the Jay Cohn New
nvestigator Award Basic Science competition), presented
ata implicating two novel pathways in the regulation of
ardiac hypertrophy and cardiomyocyte apoptosis. One of
hese involves a cyclin-dependent kinase, Cdk9, which plays
role in activating ribonucleic acid polymerase II, an
ssential element in the basal machinery for transcription of
enes. They reported that kinase activity of Cdk9 (and the
elated Cdk7) was increased in the hearts of patients with
ilated cardiomyopathy. To evaluate the significance of this,
hey studied a transgenic mouse expressing the Cdk9
ctivator, cyclin T1. The mouse demonstrated spontaneous
ypertrophy, but after imposition of a pressure load, left
entricular (LV) contractility deteriorated, and the mouse
ied within a few weeks. These studies suggest that the
ncreased activity of Cdk9 in the failing human heart may
lay a role in the progression of HF and thus could serve as
novel target in the treatment of the disorder.
The second pathway involves the DNA damage-sensing
rotein kinase, checkpoint 2 (Chk2), which Schneider and
o-workers have found to be markedly activated in the
earts of patients with advanced HF. Furthermore, this
inase is also activated by imposition of an acute pressure
oad (aortic banding) in the mouse. Schneider presented
vidence that activation of Chk2 may play a significant role
n the enhanced apoptosis seen in the failing heart. This is
urprising, because this pathway has been believed to pri-
arily function in cycling cells, not terminally differentiated
ardiomyocytes. In addition, the findings identify this path-
ay as a possible therapeutic target to block apoptosis in
atients with HF.
Dr. Helmut Drexler (Hannover Medical School, Han-
over, Germany) has previously reported that signaling
own the JAK/STAT pathway is down-regulated in pa-
ients with advanced HF. This pathway is activated by
ytokines, growth factors, and some vasoactive peptides,
ncluding angiotensin II. Drexler presented his group’s
nalysis of the phenotypes resulting from cardiac-specific
eletion in mice with STAT3 (signal transducer and acti-
ator of transcription 3), a transcription factor that induces
ene expression after cytokine stimulation. The most strik-
ng phenotype of this mouse was marked impairment of
ngiogenesis. In addition, the mouse had depressed systolic
unction and late development of HF, which was signifi-
antly accelerated by pregnancy. These findings indicate a
ritical role for STAT3 and the JAK/STAT pathway in
ardiac angiogenesis and in the maintenance of LV func-
ion.
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egulating myocardial growth, survival, and function.
r. Kenneth Walsh (Boston University School of Medi-
ine, Boston, Massachusetts) and his postdoctoral fellow,
r. Ichiro Shiojima (winner of the Jay Cohn New Investi-
ator Award for Basic Science), in their study of a mouse,
resented striking findings that tell us about the reversibility
f hypertrophic responses of the heart. In this mouse,
xpression of the prohypertrophic/anti-apoptotic protein
inase, Akt, can be suppressed by doxycycline and induced
y withdrawing the drug. Short-term induction of Akt (for
wo weeks) led to a 70% increase in heart weight, which,
emarkably, completely reverted to baseline within three
ays of turning off Akt expression with doxycycline. Pro-
onged induction (six weeks) induced marked cardiac hy-
ertrophy with severe cardiac dysfunction, and turning off
kt expression at this point led to a further decline in
ontractility. These studies demonstrate remarkably rapid
eversibility of short-term hypertrophy (though the molec-
lar mechanism is not known at this point) and also suggest
n important role for Akt in maintaining contractility in
ypertrophic/failing hearts.
Dr. John Kyriakis (Tufts University School of Medicine,
oston, Massachusetts) has identified a new mechanism by
hich growth-promoting stimuli lead to entry of cells,
ncluding vascular smooth muscle cells, into the cell cycle.
his involves a novel pathway in which a protein kinase,
ixed lineage kinase-3 (MLK-3), is essential for both
ctivation of the mitogen-activated protein kinases and
ntry into the cell cycle by growth-promoting stimuli. These
ata have important implications for the treatment of
isorders that involve unrestrained growth of vascular
mooth muscle cells and other cells, including restenosis
fter percutaneous coronary intervention (PCI). Further-
ore, they establish MLK-3 as a potential target for therapy
o block post-PCI restenosis.
ovel therapeutic strategies in HF. Dr. Elizabeth Mur-
hy (Duke University School of Medicine, Durham, North
arolina) outlined potential approaches to blocking apopto-
is in ischemic syndromes and in the hearts of patients with
F, using inhibitors of caspases and of molecular compo-
ents upstream of caspase activation. Dr. Min Nian (Uni-
ersity of Toronto, Toronto, Canada) discussed in detail
ne of these putative targets, cFLIP, in her presentation for
he Jay N. Cohn New Investigator Award competition.
Dr. Douglas Mann (Baylor College of Medicine, Hous-
on, Texas) reviewed recent data to help clarify the molec-
lar mechanisms which may have accounted for the failure
f anticytokine therapies targeting tumor necrosis factor-
lpha with etanercept (RENEWAL) and infliximab (AT-
ACH) to improve outcomes in chronic HF patients, as
ell as the mechanisms by which these therapies worsened
F in patients in the trials.
olecular imaging. Dr. Mike Modo (Institute of Psychi-try, London, United Kingdom) reviewed his group’s work An serial in vivo imaging of transplanted stem cells with
agnetic resonance imaging. Using his work on the brain as
n example, he highlighted the importance of being able to
rack the migration, survival, proliferation, and differentia-
ion of stem cells after their injection into diseased regions,
o that these could eventually be correlated with functional
ecovery (or lack thereof).
etabolic dysregulation in HF. Dr. David Carling (Im-
erial College, London, United Kingdom) reviewed recent
rogress in the regulation and function of a protein kinase
hat is believed to be a central sensing mechanism to protect
ells in the setting of adenosine triphosphate (ATP) deple-
ion, such as occurs with ischemia or intensive exercise. This
inase, the adenosine monophosphate (AMP)-activated
rotein kinase, AMPK, has become of major interest to the
harmaceutical industry, as it is believed that activators of it
ay be of benefit in the treatment of patients with meta-
olic syndrome, diabetes, and hyperlipidemia. Mutations in
MPK lead to familial hypertrophic cardiomyopathy, orig-
nally identified by Dr. Hugh Watkins and co-workers,
hich is also associated with pre-excitation and is charac-
erized by inappropriate deposition of glycogen in the heart.
arling reviewed the functional effects of these mutations
nd presented data showing that the mutations appear to
ead to partial inactivation of AMPK.
In the same session, Dr. Daniel Kelly (Washington
niversity School of Medicine, St. Louis, Missouri) pre-
ented data on novel mechanisms possibly underlying the
yocardial dysfunction seen in patients with HF, implicat-
ng metabolic abnormalities downstream of the peroxisomal
roliferator-activated receptor (PPAR)-alpha pathway and
lipotoxicity” in the development of hypertrophy and LV
ysfunction. Kelly has found that PPAR-alpha activity is
own-regulated in HF. To explore the significance of this,
he PPAR-alpha knockout mouse was crossed with a
ardiac-specific transgenic mouse overexpressing acyl coen-
yme A synthetase. This produced lipotoxicity that was
ssociated with apoptosis, fibrosis, LV dilation, and de-
ressed systolic function. This lipotoxicity could be partially
revented by substituting medium-chain triglycerides for
ong-chain triglycerides (the normal component of our
iet). These data raise the intriguing possibility that manip-
lation of dietary fat content and of PPAR-alpha activity
ould potentially alter the progression of HF in patients.
roteomics. There were two sessions focusing on pro-
eomics, the first of which was jointly sponsored by the
ational Heart, Lung, and Blood Institute (NHLBI, Na-
ional Institutes of Health, Bethesda, Maryland) and in-
luded speakers from the NHLBI (Dr. John Fakunding)
nd from four of the proteomics centers recently established
y the NHLBI—Boston University School of Medicine
Dr. Wilson Colucci), Medical University of South Caro-
ina, Charleston (Drs. Daniel Knapp and Merry Lindsey),
ohns Hopkins University, Baltimore (Dr. Jennifer van
yck), and Medical College of Wisconsin, Milwaukee (Dr.
ndrew Greene), as well as a review of the technology (Dr.
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alifornia) and a commentary on the proteomics initiative
Dr. Bruce McManus, McDonald Research Lab, Vancou-
er, Canada). In the second session, Dr. Hayes McDonald
Scripps Institute, La Jolla, California) and Dr. Don Hunt
University of Virginia, Charlottesville, Virginia) reviewed
echnologic advances in the field that will allow the identi-
cation of proteins present at 1015 mol/l concentrations
n complex mixtures of proteins (the so-called “shotgun”
pproach) and will also allow the identification of post-
ranslational modifications of these proteins (e.g., phos-
horylation, oxidation). Because so much of a cell’s response
o stimuli involves post-translational modifications of pro-
eins that are present at very low levels in the cell, the
ensitivity of these technologies should allow a much more
omprehensive understanding of the range of a cell’s re-
ponses. Importantly, these approaches take an unbiased
pproach and do not rely on “candidates” (i.e., one does not
eed to know what one is looking for before one can look
or it). These approaches may well revolutionize the field of
roteomics.
alcium regulation and arrhythmias. This session in-
luded talks by Drs. Steven Pogwizd (University of Illinois,
hicago, Illinois), Hector Valdivia (University of Wiscon-
in, Madison, Wisconsin), and Steven Houser (Temple
niversity, Philadelphia, Pennsylvania), characterizing the
ellular alterations in calcium transport and ion channels
hat contribute to depressed systolic function and triggered
rrhythmias seen in humans and animals with HF. A
educed sarcoplasmic reticulum (SR) calcium content (and
onsequent reduced calcium transients) seems to be a main
ulprit in systolic dysfunction. This is caused by a combi-
ation of reduced SR Ca-ATPase, increased Na/Ca ex-
hange, and increased SR calcium leak. Up-regulation of
a/Ca exchange and depression of potassium currents also
ncrease the propensity for triggered arrhythmias. Dr. Alan
arfinkel (University of California at Los Angeles) showed
hole-heart re-entry data and models, indicating how the
reakup of stable, spiral waves can occur, even if all cells are
dentical, and that it depends on the steepness of the
estitution of action potential duration versus cardiac cycle
ength. Finally, Dr. Rui-Ping Xiao (National Institute of
ging, Bethesda, Maryland) showed that there is complex
ross-talk between how cAMP- and calcium-calmodulin–
ependent protein kinases (PKA and CaMKII) modulate
ardiac myocyte function. This session highlighted nicely
ow understanding the cellular and molecular bases for
ltered electrophysiologic, calcium transport, and signaling
rocesses in HF may lead to novel molecular targets and
herapeutic strategies to combat acute systolic dysfunction
nd arrhythmias in HF.
ene therapy. Several presentations in this session offered
ope that gene therapy might one day offer novel therapeu-
ic approaches to patients with HF. Recombinant adeno-
ssociated viruses (rAAV) have appeared promising because
f their ability to transduce nonreplicating or slowly repli- sating cells, such as cardiomyocytes, and because they are
ot human pathogens. Dr. Jude Samulski (University of
orth Carolina, Chapel Hill, North Carolina) presented
tudies documenting the different tropisms of various rAAV
erotypes. By making use of these tropisms, as well as
ngineered, cardiac-specific promoters, Samulski showed
mpressive cardiac transduction achieved through intraperi-
oneal delivery of such vectors in animal models. Dr.
duardo Marban (Johns Hopkins University, Baltimore,
aryland) discussed genetic interventions targeted to both
radyarrhythmias and tachyarrhythmias. Proof-of-concept
xperiments were presented, documenting the ability of
ectors to specifically slow atrioventricular (AV) conduction
r, alternatively, to restore pacemaker function to
ardiomyocytes.
OCUSED SYMPOSIUM ON DIABETES AND HF
urden of diabetes and impact on HF. The global in-
rease in diabetes is also affecting HF epidemiology and
athophysiology. A symposium on this new topic was
ntroduced by Dr. Michael Fowler (Stanford University,
tanford, California). Currently, obesity is present in 20%
f the U.S. population (defined as a body mass index 30
g/m2), and obesity increases the odds of developing dia-
etes to 3.44:1. In turn, the odds of developing HF is
ncreased fourfold in young diabetic males and eightfold in
oung diabetic females. Conversely, the incidence of diabe-
es in HF patients is 20% to 25%.
The associated elevations of serum insulin and insulin
rowth factor-1 directly predict cardiovascular complica-
ions. Conversely, poor HF control also aggravates the
iabetic state. The utilization of angiotensin-converting
nzyme inhibitors, angiotensin receptor blockers, and beta-
lockers delays the onset or decreases the incidence of new
iabetes.
nsulin resistance and diabetic cardiomyopathy. Dr.
ale Abel (University of Utah, Salt Lake City, Utah)
iscussed insulin resistance and mitochondrial dysfunction
n diabetic cardiomyopathy. Normal insulin signaling is
equired for the metabolic adaptation of the heart to
ressure overload, which includes increased glycolysis, glu-
ose oxidation, and expression of GLUT1. Insulin signaling
n the heart is impaired in diabetes, and in the context of
ressure overload, these hearts develop mitochondrial and
etabolic dysfunction and early HF. These observations
ay explain why diabetes and hypertension are a potent
ombination leading to rapid development of HF.
F and PPARs. Dr. Wilson Tang (Cleveland Clinic,
leveland, Ohio) said that PPAR-gamma plays a distinct
ole in inhibiting cardiac hypertrophy and attenuates LV
emodeling after experimental MI. Thiazolidinediones are
PAR agonists, but have been associated with fluid reten-
ion in patients with HF. Indeed, thiazolidinedione users
how an increased risk of HF diagnosis, according to the
I
9
p
r
p
R
v
t
t
T
i
p
w
M
Y
t
m
g
i
d
t
A
a
t
C
H
(
s
a
e
c
a
h
e
s
w
p
z
r
p
t
c
N
(
C
Y
t
(
R
D
i
a
m
j
h
r
o
i
c
C
i
c
0
d
w
C
m
W
P
w
C
r
t
e
m
m
e
r
d
r
e
f
t
b
H
S
e
l
r
t
r
i
I
T
c
p
p
p
D
t
a
V
b
1108 Liu et al. JACC Vol. 43, No. 6, 2004
Highlights of 2003 Heart Failure Society of America March 17, 2004:1103–9nternational Classification of Diseases-9th Revision (ICD-
), from 5.5% to 8.1%, but this is only associated with
eripheral edema and actually less pulmonary edema. This
isk versus benefit should be carefully weighed in individual
atients.
ole of diabetes in acute MI. Dr. Scott Solomon (Har-
ard University, Cambridge, Massachusetts) demonstrated
hat the diabetic patient is at increased risk of MI, as well as
he adverse consequences of MI, including HF after MI.
his risk is independent of the traditional risk factors,
ncluding infarct size and ventricular remodeling. The
ost-MI diabetic patient also develops more fibrosis and
orse compliance.
anaging diabetes in the presence of HF. Dr. James
oung (Cleveland Clinic, Cleveland, Ohio) suggested that
ight glycemic control in patients with HF and diabetes
akes the HF easier to control. Each 1% increase in
lycosylated hemoglobin is directly associated with an 8%
ncrease in HF. Even if the patient does not have frank
iabetes, it is worthwhile to screen for abnormal glucose
olerance in patients with HF, as the prevalence is so high.
ggressive use of angiotensin-converting enzyme inhibitors,
ngiotensin receptor blockers, or beta-blockers will facilitate
he prevention and treatment of HF.
ARDIAC RESYNCHRONIZATION THERAPY (CRT)
ow does resynchronization work? Dr. David Kass
Johns Hopkins University, Baltimore, Maryland) demon-
trated that ventricular dyssynchrony in bundle branch block
ctually worsens LV function by requiring a higher local
nergy expenditure, inducing local molecular and metabolic
hanges in the high-stress regions of the myocardium. The
pplication of resynchronization provides immediate en-
ancement of systolic function, thus reducing wall stress and
nergy cost.
A recent detailed evaluation suggested that the LV pacing
ite has a major impact on the improvement of patients,
hereas AV delay and right ventricular/LV timing coupling
lay a relatively minor role in most patients. Resynchroni-
ation is also associated with a reduced degree of mitral
egurgitation. Resynchronization enhances the rate of LV
ressure rise, thus reducing the effective orifice area, leading
o better coordination of papillary muscles and improved
hronic chamber remodeling.
ew insights from clinical trials. Dr. William Abraham
Ohio State University, Columbus, Ohio) reported that
RT can improve indexes of quality of life, as well as New
ork Heart Association (NYHA) functional class, as seen in
he Multicenter InSync Randomized Clinical Evaluation
MIRACLE), CONTAK-CD, and Multicenter InSync
andomized Clinical Evaluation-Implantable Cardioverter
efibrillator (MIRACLE-ICD) trials. Consistently, CRTmproves exercise capacity in trials where this was tested. It plso improves cardiac function and structure, with improve-
ent in LV ejection fraction, change in mitral regurgitation
et area, and reduction in LV end-diastolic diameter.
To date, the CRT trials have shown a reduction in
ospitalization for worsening HF, but not significantly
educed mortality. Meta-analysis shows that the overall
dds ratio for hospitalization was 0.49 (95% confidence
nterval 0.25 to 0.93), in favor of CRT compared with
onventional medical therapy. In the most recently reported
omparison of Medical Therapy, Pacing and Defibrillation
n Chronic Heart Failure (COMPANION) trial, the all-
ause mortality at 12 months was reduced by 23.9% (p 
.12) in the CRT group and 43.4% in the CRT with
efibrillation (CRT-D) group (p  0.002), as compared
ith the conventional medical therapy group. In summary,
RT reduces HF and CRT-D reduces morbidity and
ortality.
ho is a candidate for resynchronization? Dr. John
arker (University of Toronto, Toronto, Canada) discussed
hich patients with HF are the most suitable candidates for
RT, in view of the high cost and ancillary resources
equired for its use. Data from clinical trials to date suggest
hat patients in NYHA functional class III/IV, with LV
jection fraction 35%, who are already maximized on
edical therapy and remain in normal sinus rhythm, are the
ost ideal candidates. On the other hand, clinical experi-
nce also suggests that patients with severe symptoms with
ecent hospitalization, low blood pressure, dilated LV end-
iastolic diameter with mitral regurgitation, high diuretic
equirement, and rising creatinine and dyssynchrony on the
chocardiogram will likely benefit.
Potential indications that are emerging on the horizon are
or patients with HF who need right ventricular pacing for
raditional indications or atrial fibrillation and right bundle
ranch block.
ow to look after resynchronization devices. Dr. Leslie
axon (University of Southern California, Los Angeles)
mphasized that attention to details in terms of short- and
ong-term programming is essential to optimize a clinical
esponse to CRT. This includes lead positioning, rate, and
ime interval considerations. The pending availability of
ight-sided hemodynamic monitoring facilities will greatly
mprove the ease with which these devices are followed.
s there still a role for the traditional pacemaker? Dr.
ony Tang (University of Ottawa, Ottawa, Canada) dis-
ussed the issue of what to do with HF patients who require
acing according to traditional indications. If the HF
atient needs a pacemaker because of bradycardia, and if the
atient has good AV conduction, then either the VVI or
DD/R mode will do. However, if AV conduction is poor,
hen the DDD/R mode will be required. If the patient has
trial fibrillation but needs only backup pacing, then the
VI/R mode may be sufficient. However, if the patient is
eing paced most of the time, then CRT with biventricular
acing will be much more appropriate.
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here were a number of new or updated clinical trials
resented at the meeting; only two with data not presented
efore at an international forum are summarized here.
he TEN-HMS trial. The purpose of the Trans-European
etwork-Home Management System (TEN-HMS) trial,
resented by Dr. John G. F. Cleland (University of Hull,
ingston-Upon-Hull, United Kingdom) is to compare
hree different strategies for following HF patients who have
een recently discharged from the hospital. They were
andomized to either: 1) usual care (traditional physician-
ased program); 2) nurse telephone service (monthly nurse
elephone call plus usual care); or 3) home telemonitoring
ith patient-initiated recording of blood pressure, weight,
nd electrocardiographic recording with automatic trans-
ission of data via a modem to a care team twice per day.
The primary outcome of the study was days lost to death
r hospitalization. The secondary end points were death,
ospitalization, or changes in medications. Ultimately, 85
atients were randomized to the usual care group, 173
atients to the nurse-managed care group, and 168 patients
o the device-monitored group. At baseline, 60% of the
atients were in NYHA functional class I or II (mean age 67
ears, mean LV ejection fraction 25%).
The percentage of days in which the patients were dead
r hospitalized was reduced from 19.5% with usual care to
5.9% for nurse-managed care and 12.7% for the combined
evice- and nurse-managed care groups. There was also an
bsolute reduction of 16.4% in mortality when comparing
he intervention versus usual care groups (p  0.05). The
ean duration of hospitalization was reduced from 17.5
ays with nurse telephone support versus 11 days with
elemonitoring (p  0.05). Patients in the telemonitoring
roup were more likely to have evidence-based medications
uccessfully implemented than were patients in either of the
ther groups. Therefore, the investigators concluded that
ncreased patient support and monitoring reduced mortality,
nd when compared with usual care, the monitoring device
trategy reduced hospital length of stay and days lost due to
eath or hospitalization and was also associated with lower
osts.
he RED-HOT trial. The Rapid Emergency Depart-
ent Heart Failure Outpatient Trial (RED-HOT), pre-
ented by Dr. Alan Maisel (San Diego VA Healthcare
ystem, San Diego, California) was designed to evaluate the
rognostic and triage role of point-of-care brain natriuretic
eptide (BNP) determination in the emergency room in
riaging a patient presenting with suspected HF, as com-
ared with the physician’s judgment alone. The hypothesiss that BNP determination may fare better than clinical
udgment.
In the RED-HOT study, 464 patients presenting with
yspnea to the emergency department with suspected HF
ere enrolled. Patients with BNP100 pg/ml, MI, or renal
ailure were excluded. The BNP level was determined on
rrival and thereafter every 3 h, but the attending physicians
ere blinded to the values.
The patients’ average age was 63 years; 54% were males
nd 50% were African-Americans. The physician-
erceived clinical status was used to categorize 76% of the
atients as being in NYHA functional class III/IV, but 90%
ere ultimately admitted. There was a significant discrep-
ncy in the physician’s assessment versus BNP measure-
ents. For example, 11% of the patients were admitted with
ctual BNP values 200 pg/ml, yet 66% were perceived by
he physician to be very sick. In contrast, in the patients
ith BNP 200 pg/ml, 76% of those were perceived to be
ery sick.
On follow-up, those patients who had initial BNP 200
g/ml had 0% and 0% mortality at 30 and 90 days,
espectively. However, those who had BNP 200 pg/ml
ccrued 4% and 7% mortality at 30 and 90 days, respectively.
he average BNP values were 976 pg/ml in those who were
ischarged versus 767 pg/ml in those who were admitted.
t 30 days, those who were alive had an average BNP value
f 764 pg/ml, as compared with an initial value of 2,000
g/ml in those who died.
The investigators concluded that patients with initial
NP values 100 pg/ml can be discharged home, whereas
hose with BNP values between 100 and 400 pg/ml should
e considered for emergency department treatment, fol-
owed by discharge if clinically stable.
UMMARY
n addition to the sessions highlighted herein, the meeting
ncluded debates, “how to” sessions, young investigator
ward competitions, late-breaking clinical trials, case dis-
ussions, bench-to-bedside sessions, as well as moderated
oster and regular poster sessions. The next Annual Scien-
ific Meeting of the Heart Failure Society of America will be
eld September 12 to 15, 2004, in Toronto, Canada
http://www.hfsa.org).
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